GlassScriptPhysician profile
Andrew A Roth
NPI 1790787521
$15,352.69
in general payments reported to CMS, 2019-2025
51 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,087 · 2020: $2,186 · 2021: $6,036 · 2022: $1,453 · 2023: $1,725 · 2024: $862 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548 · Consulting Fee: $1,040 · Education: $1.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,548.31 |
| Consulting Fee | $1,040.00 |
| Education | $1.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,905.51 | 2019-2025 | |
| Abbvie INC. | $2,061.27 | 2019-2024 | Ubrelvy, Qulipta, Orilissa |
| Novo Nordisk INC | $1,278.37 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceuticals, INC. | $1,260.28 | 2020-2021 | |
| Ibsa Pharma INC. | $1,030.61 | 2022-2023 | Tirosint, Tirosint, Licart |
| Teva Pharmaceuticals USA, INC. | $699.65 | 2019-2022 | |
| Allergan, INC. | $626.98 | 2019-2020 | |
| Amgen INC. | $596.74 | 2019-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $498.96 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $401.14 | 2019-2025 | Zepbound, Mounjaro |
| Sumitomo Pharma America, INC. | $329.66 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $325.95 | 2019-2024 | Veozah, Myrbetriq |
| Eisai INC. | $227.57 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $215.10 | 2020-2023 | Onzetra Xsail, Contrave |
| Coopersurgical, INC. | $204.77 | 2022 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.